Stable Genetic Modification of Mesenchymal Stromal Cells Using Lentiviral Vectors.
Methods Mol Biol
; 1937: 267-280, 2019.
Article
em En
| MEDLINE
| ID: mdl-30706403
ABSTRACT
Mesenchymal stromal cell (MSC) therapy has produced very promising results for multiple diseases in animal models, with over 780 clinical trials on going or completed. However, most of the human clinical trials have not been as successful as trials using preclinical models. To improve the therapeutic potential of MSCs, different research groups have used gene transfer vectors to express factors involved in migration, survival, differentiation, and immunomodulation. The ideal gene transfer vector for most applications should achieve long-term, stable (constitutive or inducible) transgene expression in MSCs and their progeny. Given their efficiency and low impact on transduced cells, lentiviral vectors (LVs) are the vectors of choice. In this chapter we will describe a detailed protocol for the generation of genetically modified MSCs using lentiviral vectors (LVs). Although this protocol has been optimized for MSC lentiviral transduction, it can be easily adapted to other stem cells by changing culture conditions while maintaining volumes and incubation times.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Lentivirus
/
Técnicas de Cultura de Células
/
Células-Tronco Mesenquimais
Tipo de estudo:
Guideline
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article